

OIE Reference Laboratory Reports Activities

Activities in 2020

This report has been submitted : 2021-01-20 14:17:26

Name of disease (or topic) for which you are a designated OIE Reference Laboratory:	African horse sickness
Address of laboratory:	LCV-Algete, Ctra. M-106 PK 1,4 28110 Algete (Madrid) SPAIN
Tel.:	(LCV)+34 913478312
Fax:	(LCV)+34 916290598
E-mail address:	maguerog@mapa.es
Website:	https://www.mapa.gob.es/en/ganaderia/temas/laboratorios/referencia-union-europea-oie/
Name (including Title) of Head of Laboratory (Responsible Official):	(LCV)Montserrat Agüero Garcia. Directora Técnica del LCV-Sanidad Animal
Name (including Title and Position) of OIE Reference Expert:	(LCV)Montserrat Agüero Garcia. Directora Técnica del LCV-Sanidad Animal
Which of the following defines your laboratory? Check all that apply:	Governmental

ToR 1: To use, promote and disseminate diagnostic methods validated according to OIE Standards

1. Did your laboratory perform diagnostic tests for the specified disease/topic for purposes such as disease diagnosis, screening of animals for export, surveillance, etc.? (Not for quality control, proficiency testing or staff training)

Yes

Diagnostic Test	Indicated in OIE Manual (Yes/No)	Total number of test performed last year	
		Nationally	Internationally
Indirect diagnostic tests			
(LCV) ELISA bloqueo	SI	920 muestras (108 plan vigilancia+110 movimientos + 185 en el marco de una infección experimental+412 preparación ensayo de intercomparación+ 350 material de referencia+ 3 diagnóstico+10 participación ensayo intercomparación)+13	18 muestras brote de Tailandia
(LCV) SNT	SI	693 muestras (60x9 serotipos preparación material de referencia +17x9 serotipos en el marco de una infección experimental)	162 muestras (17muestras del brote de Tailandia x 9 serotipos)
Direct diagnostic tests			
(LCV) Inoculación en cultivos celulares VERO	SI	25 estudio brote España 1987 + 27 en el marco de una infección experimental)	11 muestras brote Tailandia
(LCV) RRT-PCR Agüero et al; 2008 (VP7)	SI	829 muestras (316 en el marco de una infección experimental+13 material referencia+271 preparación proficiency Test+2 sueros+227 estudio brote España 1987)	172 muestras brote Tailandia (diagnóstico+ confirmación aislamiento viral)
(LCV) RRT-PCR multiplex específicas de serotipo (VP2)	NO	1296 muestras (18x 9 serotipos en el marco de una infección experimental+21x 9 serotipos preparación PT+105x9 serotipos estudio brote España 1987)	153 muestras (17x 9 serotipos brote Tailandia)

***ToR 2: To develop reference material in accordance with OIE requirements, and implement and promote the application of OIE Standards.
To store and distribute to national laboratories biological reference products and any other reagents used in the diagnosis and control of the designated pathogens or disease.***

2. Did your laboratory produce or supply imported standard reference reagents officially recognised by the OIE?

No

3. Did your laboratory supply standard reference reagents (non OIE-approved) and/or other diagnostic reagents to OIE Member Countries?

Yes

Type of reagent available	Related diagnostic test	Produced/ provide	Amount supplied nationally (ml, mg)	Amount supplied internationally (ml, mg)	No. of recipient OIE Member Countries	Region of recipients
(LCV) AHSV de los serotipos 1, 4 y 7 y EEV del serotipo 3, inactivados. Enviados en el ensayo de intercomparación organizado por el EU-RL	RT-PCR	20 ml/virus inactivado	600µl/muestra (15 muestras/participante)	600µl/muestra (15 muestras/participante)	22 países miembros de la UE (2 laboratorios en España), Suiza, Serbia, Marruecos (2 laboratorios), Túnez, Turquía, Canadá, Méjico, Sudáfrica (3 laboratorios), Emiratos Arabes, Arabia Saudí, India, Corea del Sur, Tailandia y Singapur	<input checked="" type="checkbox"/> Africa <input checked="" type="checkbox"/> Americas <input checked="" type="checkbox"/> Asia and Pacific <input checked="" type="checkbox"/> Europe <input checked="" type="checkbox"/> Middle East
(LCV) sueros equinos de animales vacunados frente al serotipo 4, de animales infectados naturalmente y experimentalmente y de caballos negativos enviados en el ensayo de intercomparación organizado por el EU-RL	ELISA	30 ml/suero	300µl/muestra (10 muestras/participante)	300µl/muestra (10 muestras/participante)	26 países miembros de la UE (2 laboratorios en España y 2 laboratorios en UK), Suiza, Serbia, Marruecos (2 laboratorios), Túnez, Turquía, Canadá, Méjico, Sudáfrica, Emiratos Arabes, Arabia Saudí, India, Corea del Sur, Tailandia y Singapur	<input checked="" type="checkbox"/> Africa <input checked="" type="checkbox"/> Americas <input checked="" type="checkbox"/> Asia and Pacific <input checked="" type="checkbox"/> Europe <input checked="" type="checkbox"/> Middle East
(LCV) sueros de referencia	ELISA		-	10 viales (0.5 ml/vial)	INDIA	<input type="checkbox"/> Africa <input type="checkbox"/> Americas <input checked="" type="checkbox"/> Asia and Pacific <input type="checkbox"/> Europe <input type="checkbox"/> Middle East
(LCV) Colección de referencia de los 9 serotipos de AHSV inactivados por calor	RT-PCR específica de serotipo		-	9 viales (0.5 ml/vial)	INDIA	<input type="checkbox"/> Africa <input type="checkbox"/> Americas <input checked="" type="checkbox"/> Asia and Pacific <input type="checkbox"/> Europe <input type="checkbox"/> Middle East
(LCV) AHSV-4 inactivado por calor	RT-PCR		-	1 vial (0.5 ml/vial)	INDIA	<input type="checkbox"/> Africa <input type="checkbox"/> Americas <input checked="" type="checkbox"/> Asia and Pacific <input type="checkbox"/> Europe <input type="checkbox"/> Middle East

(LCV) sueros de referencia	ELISA		-	10 viales (0.5 ml/vial)	TURQUIA	<input type="checkbox"/> Africa <input type="checkbox"/> Americ as <input type="checkbox"/> Asia and Pacific <input checked="" type="checkbox"/> Europe <input type="checkbox"/> Middle East
(LCV) sueros de referencia	ELISA		-	10 viales (0.5 ml/vial)	COREA DEL SUR	<input type="checkbox"/> Africa <input type="checkbox"/> Americ as <input checked="" type="checkbox"/> Asia and Pacific <input type="checkbox"/> Europe <input type="checkbox"/> Middle East
(LCV) sueros de referencia	SERONEUTRALIZACION		-	9 viales (1 ml/vial)	COREA DEL SUR	<input type="checkbox"/> Africa <input type="checkbox"/> Americ as <input checked="" type="checkbox"/> Asia and Pacific <input type="checkbox"/> Europe <input type="checkbox"/> Middle East
(LCV) Colección de referencia de los 9 serotipos de AHSV vivos	MULTIPLICACION VIRAL		-	9 viales (1 ml/vial)	COREA DEL SUR	<input type="checkbox"/> Africa <input type="checkbox"/> Americ as <input checked="" type="checkbox"/> Asia and Pacific <input type="checkbox"/> Europe <input type="checkbox"/> Middle East
(LCV) AHSV-4 inactivado por calor	RT-PCR		-	1 vial (0.5 ml/vial)	COREA DEL SUR	<input type="checkbox"/> Africa <input type="checkbox"/> Americ as <input checked="" type="checkbox"/> Asia and Pacific <input type="checkbox"/> Europe <input type="checkbox"/> Middle East
(LCV) sueros de referencia	SERONEUTRALIZACION		-	10 viales (0.5 ml/vial)	TAILANDIA	<input type="checkbox"/> Africa <input type="checkbox"/> Americ as <input checked="" type="checkbox"/> Asia and Pacific <input type="checkbox"/> Europe <input type="checkbox"/> Middle East
(LCV) Colección de referencia de los 9 serotipos de AHSV vivos	MULTIPLICACION VIRAL		-	9 viales (1 ml/vial)	TAILANDIA	<input type="checkbox"/> Africa <input type="checkbox"/> Americ as <input checked="" type="checkbox"/> Asia and Pacific <input type="checkbox"/> Europe <input type="checkbox"/> Middle East

(LCV) sueros de referencia	SERONEUTRALIZACION		-	10 viales (0.5 ml/vial)	SINGAPUR	<input type="checkbox"/> Africa <input type="checkbox"/> Americ <input checked="" type="checkbox"/> Asia <input type="checkbox"/> and <input type="checkbox"/> Pacific <input type="checkbox"/> Europe <input type="checkbox"/> Middle <input type="checkbox"/> East
(LCV) sueros de referencia	SERONEUTRALIZACION			10 viales (0.5 ml/vial)	AUSTRALIA	<input type="checkbox"/> Africa <input type="checkbox"/> Americ <input checked="" type="checkbox"/> Asia <input type="checkbox"/> and <input type="checkbox"/> Pacific <input type="checkbox"/> Europe <input type="checkbox"/> Middle <input type="checkbox"/> East

4. Did your laboratory produce vaccines?

No

5. Did your laboratory supply vaccines to OIE Member Countries?

No

ToR 3: To develop, standardise and validate, according to OIE Standards, new procedures for diagnosis and control of the designated pathogens or diseases

6. Did your laboratory develop new diagnostic methods validated according to OIE Standards for the designated pathogen or disease?

No

7. Did your laboratory develop new vaccines according to OIE Standards for the designated pathogen or disease?

No

ToR 4: To provide diagnostic testing facilities, and, where appropriate, scientific and technical advice on disease control measures to OIE Member Countries

8. Did your laboratory carry out diagnostic testing for other OIE Member Countries?

Yes

Name of OIE Member Country seeking assistance	Date (month)	No. samples received for provision of diagnostic support	No. samples received for provision of confirmatory diagnoses
THAILAND	MAYO	-	18 muestras de suero, 8 muestras de sangre EDTA, 3 muestras de homogeneizado de tejidos y 6 muestras de ARN

9. Did your laboratory provide expert advice in technical consultancies on the request of an OIE Member Country?

Yes

Name of the OIE Member Country receiving a technical consultancy	Purpose	How the advice was provided
THAILAND	Control del brote y seguimiento post vacunación del mismo	Vía correo electrónico
MYANMAR	Soporte para tener a punto las técnicas de diagnóstico	Vía correo electrónico
KAZAKHSTAN	Soporte para tener a punto las técnicas de diagnóstico	Vía correo electrónico
KYRGYZSTAN	Soporte para tener a punto las técnicas de diagnóstico	Vía correo electrónico
KOREA (REP. OF)	Soporte para tener a punto las técnicas de diagnóstico	Vía correo electrónico
MALAYSIA	Soporte para tener a punto las técnicas de diagnóstico, y asesoramiento para el control de la enfermedad	Vía correo electrónico

ToR 5: To carry out and/or coordinate scientific and technical studies in collaboration with other laboratories, centres or organisations

10. Did your laboratory participate in international scientific studies in collaboration with OIE Member Countries other than the own?

No

ToR 6: To collect, process, analyse, publish and disseminate epizootiological data relevant to the designated pathogens or diseases

11. Did your Laboratory collect epizootiological data relevant to international disease control?

Yes

If the answer is yes, please provide details of the data collected:
(LCV)Se participó en la identificación del serotipo de Peste Equina del brote de Tailandia así como el aislamiento del virus y el diagnóstico serológico de muestras clínicas procedentes del brote.

12. Did your laboratory disseminate epizootiological data that had been processed and analysed?

No

If the answer is no, please provide a brief explanation of the situation:
La información de las muestras clínicas se envió a las Autoridades de Tailandia con copia a la OIE y a la Comisión de la UE. Además se difundió en el Workshop de Lengua azul y Peste equina, organizado por el LCV y realizado por vía telemática los días 1 y 2 de diciembre de 2020.

**13. What method of dissemination of information is most often used by your laboratory?
(Indicate in the appropriate box the number by category)**

a) Articles published in peer-reviewed journals: 0

b) International conferences: 3

- OIE Webinar series on "African horse sickness":

R. Villalba: "Webinar #2: African horse sickness: diagnostic tests and possible support from OIE Reference Laboratories"

- 2020 OIE Regional Events in Asia and the Pacific

R. Villalba: "Support from the OIE Reference Laboratories"

- EU African Horse Sickness and Bluetongue Reference Laboratories Webinars 2020 (1-2 Diciembre, Madrid, España:

R. Villalba: "Activities of the AHS EURL"

R. Villalba/C.Tena: "AHS Proficiency test results"

c) National conferences: 0

d) Other:

(Provide website address or link to appropriate information) 0

ToR 7: To provide scientific and technical training for personnel from OIE Member Countries

To recommend the prescribed and alternative tests or vaccines as OIE Standards

14. Did your laboratory provide scientific and technical training to laboratory personnel from other OIE Member Countries?

No

ToR 8: To maintain a system of quality assurance, biosafety and biosecurity relevant for the pathogen and the disease concerned

15. Does your laboratory have a Quality Management System?

Yes

Quality management system adopted	Certificate scan (PDF, JPG, PNG format)
(LCV) UNE EN ISO 17025	5-.certificado Acreditacion ENAC_LE-1530_02.08.2018_sello electronico.pdf
(LCV) UNE EN ISO 14001	3-.CertificadoGA-2002-0327_ES_2020-11-06.pdf

16. Is your quality management system accredited?

Yes

Test for which your laboratory is accredited	Accreditation body
(LCV) Detección de anticuerpos frente al VPEA mediante ELISA en sueros de équidos	ENAC
(LCV) Detección de orbivirus mediante cultivo celular (BTV, AHSV, EHDV) en muestras de sangre completa no coagulada, bazo, pulmón y nódulos linfáticos	ENAC
(LCV) Detección-identificación del VPEA mediante RT-PCR a tiempo real en muestras de vísceras de animales, sangre y cultivos celulares	ENAC
(LCV) Serotipificación de anticuerpos frente a Orbivirus por neutralización (BTV, AHSV, EHDV) en suero de rumiantes y équidos	ENAC
(LCV) Tipificación del VPEA mediante RT-PCR a tiempo real en muestras de vísceras de animales, sangre y cultivos celulares	ENAC

17. Does your laboratory maintain a “biorisk management system” for the pathogen and the disease concerned?

Yes

(See Manual of Diagnostic Tests and Vaccines for Terrestrial Animals, Chapter 1.1.4)

ToR 9: To organise and participate in scientific meetings on behalf of the OIE

18. Did your laboratory organise scientific meetings on behalf of the OIE?

No

19. Did your laboratory participate in scientific meetings on behalf of the OIE?

Yes

Title of event	Date (mm/yy)	Location	Role (speaker, presenting poster, short communications)	Title of the work presented
OIE Webinar series on "African horse sickness"	15/04/2020	Web	Orador	R.Villalba:"Webinar #2: African horse sickness: diagnostic tests and possible support from OIE Reference Laboratories"
2020 OIE Regional Events in Asia and the Pacific	22/06/2020	Web	Orador	R.Villalba:"Support from the OIE Reference Laboratories"

ToR 10: To establish and maintain a network with other OIE Reference Laboratories designated for the same pathogen or disease and organise regular inter-laboratory proficiency testing to ensure comparability of results

20. Did your laboratory exchange information with other OIE Reference Laboratories designated for the same pathogen or disease?

Yes

21. Was your laboratory involved in maintaining a network with OIE Reference Laboratories designated for the same pathogen or disease by organising or participating in proficiency tests?

Yes

Purpose of the proficiency tests: ¹	Role of your Reference Laboratory (organiser/ participant)	No. participants	Participating OIE Ref. Labs/ organising OIE Ref. Lab.
(LCV) Ensayo interlaboratorial	Organizadores y Participantes	46	Lab. Ref. OIE organizador: LCV (Spain) Lab. Ref. OIE AHS Participantes: -The Pirbright Institute (UK) - LCV (Spain) -OVI (South Africa)

¹ validation of a diagnostic protocol: specify the test; quality control of vaccines: specify the vaccine type, etc.

22. Did your laboratory collaborate with other OIE Reference Laboratories for the same disease on scientific research projects for the diagnosis or control of the pathogen of interest?

No

ToR 11: To organise inter-laboratory proficiency testing with laboratories other than OIE Reference Laboratories for the same pathogens and diseases to ensure equivalence of results

23. Did your laboratory organise or participate in inter-laboratory proficiency tests with laboratories other than OIE Reference Laboratories for the same disease?

Yes

Note: See Interlaboratory test comparisons in: Laboratory Proficiency Testing at: <http://www.oie.int/en/our-scientific-expertise/reference-laboratories/proficiency-testing> see point 1.3

Purpose for inter-laboratory test comparisons ¹	No. participating laboratories	Region(s) of participating OIE Member Countries
(LCV)Organización de un ensayo de intercomparación, como EU-RL, de aptitud para la evaluación de métodos de diagnóstico (detección de anticuerpos y genoma viral)	46	<input checked="" type="checkbox"/> Africa <input checked="" type="checkbox"/> Americas <input checked="" type="checkbox"/> Asia and Pacific <input checked="" type="checkbox"/> Europe <input checked="" type="checkbox"/> Middle East

ToR 12: To place expert consultants at the disposal of the OIE

24. Did your laboratory place expert consultants at the disposal of the OIE?

No

25. Additional comments regarding your report: